Back

The prognostic value of sodium-glucose co-transporter-2 inhibitors therapy among patients with cancer and diabetes mellitus, treated with immune checkpoint inhibitors

21 May 2023 (13:26 - 14:20)
Organised by: Logo
Congress Presentation Part of: ePosters in cardiovascular disease in special populations 1 Cardio-Oncology HFA Premium Access Heart Failure 2023 Heart Failure Association (HFA)

About the speaker

Photo
Associate Professor Michal Laufer-Perl

Tel Aviv Sourasky Medical Center, Tel Aviv (Israel)

6 More presentations in this session

Presentation thumbnail
A new maternal heart clinic - early experiences and challenges in a quaternary hospital in Western Australia.
Doctor R. Chetty (Perth, AU)
Abstract Slides
Presentation thumbnail
Safety and utility of cardiopulmonary exercise testing in non-Hodgkin lymphoma patients undergoing chemotherapy
Doctor D. Bursacovschi (Chisinau, MD)
Abstract Slides
Presentation thumbnail
Plasminogen activator inhibitor -1 and circulating ceruloplasmin levels in men with heart failure with preserved ejection fraction with concomitant prostate cancer
Doctor O. Sirenko (Dnipro, UA)
Abstract Slides
Presentation thumbnail
Relationship between clinical and echocardiographic outcomes and cardioprotective drugs in a population of female breast cancer patients exposed to anthracyclines
Doctor C. Oliveira (Porto, PT)
Abstract Slides
Presentation thumbnail
Impact of a cardio-oncology unit on prevention of cardiovascular events in cancer patients
Doctor A. Cuomo (Naples, IT)
Abstract Slides

Access the full session

Session thumbnail
ePosters in cardiovascular disease in special populations 1

The Event

Event poster

Heart Failure 2023

21 May 2023 13:26 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources